Catalyst brief · Phase 3 readout · 26 days
ENGAGE: Solriamfetol 150 mg in Binge-Eating Disorder
Axsome Therapeutics, Inc. · $AXSM · built 19 Nov 2026 from 19 sourced facts · open on the radar
Analyst desk
Five AI analysts read the facts below. Each sentence shows the facts it rests on.
Trial design
Base rates
- Historically, 53.9% of Phase 3 programmes in neurology moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F13
- AXSM has had an average absolute share move of 6.9% on past trial-result days, but this is just an average and not a forecast for this event. F15
Filings
- The company has $314M in cash and short-term investments, which is expected to last around 46 months, well beyond the trial's primary completion date. F16 F17
- There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F18
- The company has reported an FDA decision date of 1 May 2027 in an SEC filing. F19
The case for
The case against
- The trial may not finish on time, as 20% of AXSM's active Phase 2 and 3 trials have had their dates moved back by more than 6 months, which could impact the ENGAGE trial's timeline. F14
- With 53.9% of Phase 3 programmes in neurology moving on to a regulatory filing, there is a significant chance that the ENGAGE trial may not meet its primary goal, leading to a failed trial or delayed regulatory process. F13
Open questions
- Will Solriamfetol 150 mg show a statistically significant reduction in binge eating episodes over 12 weeks?
- Will the ENGAGE trial meet its primary completion date as estimated in the registry?
- Will a positive outcome in the ENGAGE trial lead to a regulatory filing by Axsome Therapeutics?
9 AI sentences were removed by the fact check.
The facts
The trial
- F1ENGAGE is a Phase 3 trial of Solriamfetol 150 mg in Binge-Eating Disorder, sponsored by Axsome Therapeutics, Inc. (AXSM). source ↗
- F2The trial plans to enrol 450 patients. source ↗
What counts as success
- F3Main goal as written in the registry: Change from Baseline to Week 12 in number of binge eating episodes. source ↗
- F4Blinding: double blind. source ↗
- F5Allocation: randomised. source ↗
- F6The main goal is measured over: 12 weeks. source ↗
- F7Number of study arms: 3. source ↗
When
- F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
- F10That date is 12.0 months later than the date first registered for this trial (Dec 2025). source ↗
- F11In a filing of 2 Nov 2026 the company told investors to expect data in Q1 2027. This agrees with the registry date. source ↗
- F12The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗
Recruitment
- F8The registry lists 45 sites, of which 7 have closed. source ↗
Base rates
- F13Historically 53.9% of Phase 3 programmes in neurology (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
- F1420% of AXSM's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗
- F15AXSM has had 5 past trial-result days on record, with an average absolute share move of 6.9%. source ↗
Money, insiders and FDA
- F16AXSM reported $314M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
- F17At the last 12 months' rate of spending (about $7M a month) that cash lasts about 46 months, to around Aug 2030, which is after the registry's primary completion date. source ↗
- F18No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗
- F19AXSM has reported an FDA decision date of 1 May 2027 in an SEC filing. source ↗
How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.